Emerging Markets Clinical Trials: Asia

$995.00

This study is designed to address challenges and answer burning questions about conducting clinical trials in Asia. The report includes detailed data on China and India as well as information on trials in Malaysia, Hong Kong, Taiwan, Thailand, Singapore, South Korea and the Philippines.  Use the benchmarks, metrics and best practices to avoid common pitfalls and solidify your clinical trials in Asia.

Download a benchmarking report summarySpeak to a pharmaceutical benchmarking expert

Report Details

Publication Date: November 2010
Pages: 193
Chapters: 3
Metrics: 400+
Charts/Graphics: 120+
Profiles: 20

Top Reasons to Buy this Emerging Markets Clinical Development in Asia Report

Address Intellectual Property Concerns in Emerging Markets Clinical Development Research Markets:  Asia has a reputation for poor intellectual property protections, and this report uncovers the progress made in China, India and other Asian nations around IP protection. The report will also help you navigate regulations, healthcare infrastructure, costs and patient access.

Benefit from Strong Physician-Patient Relationships:  Learn about the strong physician-patient relationships created in different Asian countries. Tap into these bonds to boost enrollment and retention for your clinical studies.

Explore Individual Country Benefits:  Too often, companies approach specific emerging markets with regional strategies. This report illustrates the benefits that each individual country provides so that you can develop detailed plans for running trials in each market. Tap into the best ratios of cost, quality and timelines while using local partners to navigate culture, communication and regulations.

You may also be interested in CEIConnect: The Lifesciences Industry’s On-Demand Research Resource as well as our individual clinical development research reports.

Excerpt from Emerging Markets Clinical Development in Asia

With the economy questionable, patent cliffs inevitable and pipelines scarce, pharmaceutical and device companies look to utilize their resources in the most efficient manner possible. Significant promise lies in clinical development, but companies encounter many challenges in this area. On top of every company’s list is patient recruitment.

With tens of thousands of trials registered in the US and Western Europe alone, companies sometimes find it impossible to meet the patient enrollment numbers to complete their clinical trials. The blame for this problem has been placed on everyone from the FDA/EMEA (impossibleto-meet protocols) to physicians (overmedicating potential patients) to patients (for not caring about research) to the companies themselves for running too many trials, many of which will not end in groundbreaking results.

Table of Contents

9              Clinical Development in Asia: Harnessing the Best of the East and West

11           Scoring Asia

30           Study Methodology

31           Participating Companies

32           Report Layout

33           Profile Layout

36           Running Trials in Asia: Key Recommendations for Success

43           China

44           Clinical Environment Overview

58           Clinical Development Strategy

74           Clinical Development Profiles

95           India

96           Clinical Environment Overview

10           9 Clinical Development Strategy

130         Clinical Development Profiles

159         Other Emerging Asian Countries

162         Clinical Development Profiles

Charts and Graphics

Executive Summary

Scoring Asia

12           Figure E.1: Asian Population Compared to US and 5 EU Countries

13           Figure E.2: Number of Studies Registered by Region

13           Figure E.3: Number of Studies Registered in Profiled Asian Countries

15           Figure E.4: Scoring Asia: Patient Access

15           Figure E.5: Scoring Asia: Patient Retention

17           Figure E.6: Scoring Asia: Regulatory Environment

18           Figure E.7: Scoring Asia: Intellectual Property Laws/Practice

20           Figure E.8: Scoring Asia: Cultural Concerns

20           Figure E.9: Scoring Asia: Communication/Language

22           Figure E.10: Scoring Asia: Trial Technology Infrastructure

22           Figure E.11: Scoring Asia: Supply Chain Management

24           Figure E.12: Scoring Asia: Available Knowledge Base

25           Figure E.13: Scoring Asia: Data Standards

25           Figure E.14: Scoring Asia: Investigator Standards

26           Figure E.15: Scoring Asia: Site Management Standards

27           Figure E.16: Average Percentage of Budget Saved by Running a Site in Asia

28           Figure E.17: Average Percentage of Time Saved by Running a Site in Asia

29           Figure E.18: Scoring Asia: Anticipated Cost

China

Clinical Development Strategy

44           Table 1.1: Key Demographic Figures for China (2010)

45           Figure 1.1: Change in Life Expectancy: China (1960–2050)

46           Table 1.2: Top 10 Causes of Death in China (2002)

47           Figure 1.2: Ethnicities in China (2000 Census)

50           Table 1.3: China’s Key Economic Figures (2009)

52           Table 1.4: China’s Key Healthcare System Figures, 2005-2009

53           Figure 1.3: China Healthcare Spending as a Percentage of GDP (2009)

54           Figure 1.4: China’s Health Spending by Sector (2005)

Clinical Environment Overview

60           Figure 1.5: Percentage of Budget Saved by Running a Trial in China

60           Figure 1.6: Percentage of Time Saved by Running a Trial in China

61           Figure 1.7: Assigning Clinical Development Responsibilities for China

63           Figure 1.8: Scoring China: Clinical Environment Scores

64           Figure 1.9: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in China

69           Figure 1.10: Importance of Factors that Impact Trial Operations for Companies Operating in China

70           Figure 1.11: Scoring China: Trial Operations Scores

73           Figure 1.12: Percent of Total Trial Patients Enrolled in China

Clinical Development Profiles

74           Figure 1.13: Profile 1: Company Background

75           Figure 1.14: Profile 1: Experience in Asia

76           Figure 1.15: Profile 1: Clinical Strategy in China

77           Figure 1.16: Profile 1: Scorecard for China

78           Figure 1.17: Profile 2: Company Background

79           Figure 1.18: Profile 2: Experience in Asia

80           Figure 1.19: Profile 2: Clinical Strategy in China

81           Figure 1.20: Profile 2: Scorecard for China

82           Figure 1.21: Profile 3: Company Background

83           Figure 1.22: Profile 3: Experience in Asia

84           Figure 1.23: Profile 3: Clinical Strategy in China

85           Figure 1.24: Profile 3: Scorecard for China

86           Figure 1.25: Profile 4: Company Background

87           Figure 1.26: Profile 4: Experience in Asia

88           Figure 1.27: Profile 4: Clinical Strategy in China

89           Figure 1.28: Profile 4: Scorecard for China

90           Figure 1.29: Profile 5: Company Background

91           Figure 1.30: Profile 5: Experience in Asia

92           Figure 1.31: Profile 5: Clinical Strategy in China

93           Figure 1.32: Profile 5: Scorecard for China

India

Clinical Environment Overview

97           Table 2.1: Key Demographic Figures for India (2010)

98           Figure 2.1: Change in Life Expectancy (1960-2050)

99           Table 2.2: Top Ten Causes of Death in India (2002)

101         Figure 2.2: Ethnicities in India (2000 Census)

103         Table 2.3: Key Economic Figures (2009)

104         Figure 2.3: India’s Healthcare Spending as a Percent of GDP (2006)

105         Figure 2.4: Health Spending by Sector (2005)

106         Table 2.4: Key Healthcare System Figures (2005–2009)

Clinical Development Strategy

110         Figure 2.5: Assigning Clinical Development Responsibilities for India

115         Figure 2.6: Importance of Factors that Impact Clinical Trial Environment for Companies Operating in India

116         Figure 2.7: Scoring India: Clinical Environment Scores

123         Figure 2.8: Importance of Factors that Impact Trial Operations for Companies Operating in India

123         Figure 2.9: Scoring India: Trial Operations Scores

125         Figure 2.10: Percent of Total Trial Patients Enrolled in India

128         Figure 2.11: Percentage of Budget Saved by Running a Trial in India

128         Figure 2.12: Percentage of Time Saved by Running a Trial in India

Clinical Development Profiles

130         Figure 2.13: Profile 6: Company Background

131         Figure 2.14: Profile 6: Experience in Asia

132         Figure 2.15: Profile 6: Clinical Strategy in India

133         Figure 2.16: Profile 6: Scorecard for India

134         Figure 2.17: Profile 7: Company Background

135         Figure 2.18: Profile 7: Experience in Asia

136         Figure 2.19: Profile 7: Clinical Strategy in India

137         Figure 2.20: Profile 7: Scorecard for India

138         Figure 2.21: Profile 8: Company Background

139         Figure 2.22: Profile 8: Experience in Asia

140         Figure 2.23: Profile 8: Clinical Strategy in India

141         Figure 2.24: Profile 8: Scorecard for India

142         Figure 2.25: Profile 9: Company Background

143         Figure 2.26: Profile 9: Experience in Asia

144         Figure 2.27: Profile 9: Clinical Strategy in India

145         Figure 2.28: Profile 9: Scorecard for India

146         Figure 2.29: Profile 10: Company Background

147         Figure 2.30: Profile 10: Experience in Asia

148         Figure 2.31: Profile 10: Clinical Strategy in India

149         Figure 2.32: Profile 10: Scorecard for India

150         Figure 2.33: Profile 11: Company Background

151         Figure 2.34: Profile 11: Experience in Asia

152         Figure 2.35: Profile 11: Clinical Strategy in India

153         Figure 2.36: Profile 11: Scorecard for India

154         Figure 2.37: Profile 12: Company Background

155         Figure 2.38: Profile 12: Experience in Asia

156         Figure 2.39: Profile 12: Clinical Strategy in India

157         Figure 2.40: Profile 12: Scorecard for India

Other Emerging Asian Countries

Clinical Development Profiles

162         Figure 3.1: Profile 13: Company Background

163         Figure 3.2: Profile 13: Experience in Asia

164         Figure 3.3: Profile 13: Clinical Strategy in Hong Kong

165         Figure 3.4: Profile 13: Scorecard for Hong Kong

166         Figure 3.5: Profile 14: Company Background

167         Figure 3.6: Profile 14: Experience in Asia

168         Figure 3.7: Profile 14: Clinical Strategy in Malaysia

169         Figure 3.8: Profile 14: Scorecard for Malaysia

170         Figure 3.9: Profile 15: Company Background

171         Figure 3.10: Profile 15: Experience in Asia

172         Figure 3.11: Profile 15: Clinical Strategy in Philippines

173         Figure 3.12: Profile 15: Scorecard for Philippines

174         Figure 3.13: Profile 16: Company Background

175         Figure 3.14: Profile 16: Experience in Asia

176         Figure 3.15: Profile 16: Clinical Strategy in Singapore

177         Figure 3.16: Profile 16: Scorecard for Singapore

178         Figure 3.17: Profile 17: Company Background

179         Figure 3.18: Profile 17: Experience in Asia

180         Figure 3.19: Profile 17: Clinical Strategy in South Korea

181         Figure 3.20: Profile 17: Scorecard for South Korea

182         Figure 3.21: Profile 18: Company Background

183         Figure 3.22: Profile 18: Experience in Asia

184         Figure 3.23: Profile 18: Clinical Strategy in Taiwan

185         Figure 3.24: Profile 18: Scorecard for Taiwan

186         Figure 3.25: Profile 19: Company Background

187         Figure 3.26: Profile 19: Experience in Asia

188         Figure 3.27: Profile 19: Clinical Strategy in Thailand

189         Figure 3.28: Profile 19: Scorecard for Thailand

190         Figure 3.29: Profile 20: Company Background

191         Figure 3.30: Profile 20: Experience in Asia

192         Figure 3.31: Profile 20: Clinical Strategy in Thailand

193         Figure 3.32: Profile 20: Scorecard for Thailand